PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results
Demonstrate Safety and Efficacy at Once-Weekly Dosing
... Diabetes Patients -
MONTREAL, March 26 /CNW/ - conjuchem
(TSX:CJB) today announced p...d effective in lowering blood glucose levels."
intends to submit the study results for presentati...7.
In conjunction with the multi-dose results, conjuchem
reported that ongoing product development p...
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin
Conjugate Data Presented at American Diabetes Association Annual
... MONTREAL, June 19 /CNW/ - conjuchem
today announced that da... a small volume with a small gauge
ConjuChem, developer of next generation medicine...ion: Lennie Ryer, CA, Vice President
Finance, CFO, conjuchem
Biotechnologies Inc., (514) 844-5558 ext
ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
...AGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - conjuchem
Biotechnologies Inc. (TSX:CJB) and Novozymes Bioph...TM):Exendin-4 increases. The Agreement also allows conjuchem
to fully assign all rights to a PC-DAC(TM):Exendin-4 licensee.
In a separate Agreement, conjuchem
and Novozymes Biopharma entered into a Pipeline Pr...
ConjuChem Provides Development Update
...sults - MONTREAL, Nov. 5 /PRNewswire-FirstCall/ - conjuchem
Inc. (TSX:CJB) announced today tha...umin(R), provided
by Novozymes Biopharma).
Biotechnologies, developer of next generation medi...
Aegera Therapeutics welcomes two experienced executives to its board of directors
...h Capital Management - Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital - Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, conjuchem
The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of
Aegera's Board Members can be viewed at http://www.aegera.com